This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00063/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00063/identifier/wikipedia/
n25http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://www.rxlist.com/cgi/generic/
n8http://linked.opendata.cz/resource/drugbank/patent/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00063/identifier/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00063/identifier/national-drug-code-directory/
n23http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00063
rdf:type
n3:Drug
n3:description
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.
n3:dosage
n19:271B42DD-363D-11E5-9242-09173F13E4C5 n19:271B42DE-363D-11E5-9242-09173F13E4C5 n19:271B42DF-363D-11E5-9242-09173F13E4C5 n19:271B42E0-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Nguyen CM, Harrington RA: Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003;3(6):423-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/ 14728062
n3:group
approved investigational
n3:halfLife
Approximately 2.5 hours
n3:indication
For treatment of myocardial infarction and acute coronary syndrome.
n3:manufacturer
n4:271B42D9-363D-11E5-9242-09173F13E4C5
owl:sameAs
n16:DB00063 n25:DB00063
dcterms:title
Eptifibatide
adms:identifier
n6:Eptifibatide n11:0085-1177-01 n12:PA449483 n13:DB00063
n3:mechanismOfAction
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.
n3:packager
n4:271B42D8-363D-11E5-9242-09173F13E4C5 n4:271B42D6-363D-11E5-9242-09173F13E4C5 n4:271B42D7-363D-11E5-9242-09173F13E4C5 n4:271B42D4-363D-11E5-9242-09173F13E4C5 n4:271B42D5-363D-11E5-9242-09173F13E4C5
n3:patent
n8:5807825 n8:5686570 n8:2133205
n3:synonym
Intrifiban Integrelin
n3:toxicity
Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis)
n22:hasAHFSCode
n24:20-12-18
n3:proteinBinding
Approximately 25%
n3:synthesisReference
Guojie Ho, Antoinette Paone, Luciano Forni, Catherine De Tollenaere, Brice Bonnet, Christine Devijver, "Processes for preparing eptifibatide." U.S. Patent US20060036071, issued February 16, 2006.
n9:hasConcept
n10:M0229697
foaf:page
n18:eptifibatide.html n21:eptifibatide.htm
n3:Molecular-Formula
n7:271B42E3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B42E2-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:B01AC16
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
188627-80-7
n3:category
n3:clearance
* 55 mL/kg/h [patients with coronary artery disease]
n3:containedIn
n20:271B42DA-363D-11E5-9242-09173F13E4C5 n20:271B42DB-363D-11E5-9242-09173F13E4C5 n20:271B42DC-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n7:271B42E1-363D-11E5-9242-09173F13E4C5